Fennec Pharmaceuticals Inc. (FENC), Friday announced that the National Institute for Health and Care Excellence or NICE has recommended Pedmarqsi, intended for the prevention of Cisplatin-induced hearing loss in patients with localized, non-metastatic, solid tumors.
The pharmaceutical company added that the findings from two open-label, randomized Phase 3 trials, SIOPEL 6 and the Clinical Oncology Group Protocol ACCL0431 demonstrated around 50 percent reduction in the occurrence of cisplatin-induced hearing loss in patients treated with cisplatin and sodium thiosulfate.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.